Cetuximab Completed Phase 2 Trials for Endometrial Cancer Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00392769Cetuximab in Patients With Progressive or Recurrent Endometrial Cancer